Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Inflazome logo — Inflazome develops drugs to block inflammasome signals, redu...

Inflazome

Inflazome develops drugs to block inflammasome signals, reducing unwanted inflammation associated with diseases.

Founded 2016 2-10 employees Grant Total: $58.00M Biopharma, Biotechnology +1

General Information

Company Name Inflazome
Founded Year 2016
Employees 2-10
Industries Biopharma, Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Inflazome. To contact Inflazome, visit inflazome.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inflazome compare?

A PDF of Inflazome and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inflazome soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inflazome

Inflazome is a biopharmaceutical startup founded in 2016 that is devoted to developing groundbreaking drugs aimed at blocking inflammasome signals, thus reducing unwanted inflammation associated with various diseases. The company's mission is reflected in their slogan: "Inflazome develops drugs to block inflammasome signals, reducing unwanted inflammation associated with diseases." Inflammasomes play a vital role in governing our innate immune response and have been linked to a myriad of diseases. Inflazome's focus lies in creating inhibitors for the inflammasome, aiming to thwart uncontrollable immune cell activation, which can lead to detrimental inflammation. Their inhibitors are designed to effectively obstruct inflammasome signals, targeting a fundamental source of inflammation. Inflazome's innovative approach holds promise in addressing conditions where inflammation is a key contributing factor to disease progression. The startup has garnered investor interest, with their last investment coming in the form of a $1.00M grant on 25 March 2019, with funding provided by the Michael J. Fox Foundation. This investment not only highlights the confidence that notable organizations have in Inflazome's endeavors but also underscores the potential impact of their work in the biopharma and biotechnology industries. In summary, Inflazome's innovative approach in developing inhibitors for the inflammasome presents a promising avenue for addressing diseases associated with inflammation. Their recent funding from the Michael J. Fox Foundation underlines the recognition of their potential within the biopharmaceutical landscape.

Business keywords: inflammasome inhibitors, biological target, innate immune response, disease treatment, immune system modulation, drug development, inflammation, immune response regulation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.00M 1
The Michael J. Fox Foundation for Parkinson's Research
The Michael J. Fox Foundation for Parkinson's Research
25 Mar 2019
Series B €40.00M 1
Forbion
Forbion
19 Nov 2018
Series A $17.00M 2
Novartis Venture Fund Fountain Healthcare Partners
Novartis Venture Fund, Fountain Healthcare Partners
11 Sep 2016

Inflazome Alternatives & Competitors

View All Alternatives
Inflazome vs
NodThera
NodThera United States

Treating chronic disease by targeting inflammation at its source

Series B
22 employees
Biotechnology, Health Care
Inflazome vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Venture round
9 employees
Biotechnology, Health Care
Inflazome vs
Azome Therapeutics
Azome Therapeutics

Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases

Seed
3 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Inflazome

Inflazome develops drugs to block inflammasome signals, reducing unwanted inflammation associated with diseases.
Inflazome was founded in 2016.
Inflazome operates in Biopharma, Biotechnology and Health Care. Its work centres on inflammasome inhibitors, biological target, innate immune response and disease treatment.
Inflazome has approximately 2-10 employees.
Inflazome has completed 3 funding rounds, raising a total of $58.00M. The latest funding stage is Grant.
Top alternatives and competitors to Inflazome include NodThera, Tolerx, Inc., Azome Therapeutics, Coley Pharmaceutical Group, Elicio Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inflazome and NodThera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inflazome, https://bouncewatch.com/company/inflazome, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout